Alibaba Health Information Technology Ltd
Alibaba Health Information Technology Ltd operates in the drug retailing industry, providing online and offline healthcare services and products, including pharmaceuticals, medical devices, and health information technology solutions.
Business. Alibaba Health Information Technology Ltd (0241.HK) is a drug retailer operating within the Food & Drug Retailing industry. The company generates revenue primarily through product sales. It is listed on the Hong Kong Stock Exchange. Specific details regarding operating segments and geographic mix are not available.
Analyst recommendations
17 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Alibaba Health Information Technology Ltd (0241.HK) is a drug retailer operating within the Food & Drug Retailing industry. The company generates revenue primarily through product sales. It is listed on the Hong Kong Stock Exchange. Specific details regarding operating segments and geographic mix are not available.
Alibaba Health has a market capitalization of 61.14 billion CNY, with a current market price of 3.78 CNY per share. The company's basic and diluted shares outstanding are equal at 16.18 billion, indicating no immediate dilution from share-based compensation or convertible instruments. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
Profitability metrics are not available in the provided data, but the company's market price is below the mean and median analyst price targets of 5.83 CNY and 5.48 CNY, respectively, suggesting potential upside in valuation. Analysts have issued 4 strong-buy, 6 buy, and 5 hold recommendations, indicating a generally positive outlook despite the current price being below the median target.
The company's revenue concentration and geographic exposure are not disclosed in the available data, but as a major player in China's healthcare retail market, it is likely to be heavily concentrated in domestic operations. This could expose the company to regulatory and macroeconomic risks specific to the Chinese market.
Outlook data is not provided in the input, but the current price is below the analyst price targets, suggesting a potential growth trajectory. The absence of detailed revenue history and outlook data limits the ability to assess the company's growth potential quantitatively.
The company's risk assessment indicates low dilution risk, with no immediate pressure from share-based compensation or convertible instruments. However, the lack of liquidity data and the absence of going-concern language in source documents suggest that the company's financial health and operational stability should be closely monitored.
Recent events and filings are not detailed in the input, but the company's current market price and analyst price targets suggest that it is under active scrutiny by investors and analysts. The absence of detailed recent events data limits the ability to assess the company's current strategic direction and operational performance.
- Alibaba Health's market price is below the mean and median analyst price targets, indicating potential upside.
- The company has a low dilution risk, with basic and diluted shares outstanding being equal.
- Liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
- Analysts have issued a generally positive outlook, with 4 strong-buy, 6 buy, and 5 hold recommendations.
- The company's revenue concentration and geographic exposure are not disclosed, but it is likely to be heavily concentrated in domestic operations in China.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Revenue ¥34.26B, +11,9% YoY.
- ▍Revenue ¥34.26B, +11,9% YoY
Revenue ¥30.60B, +13,2% YoY; Operating income +71,1% YoY.
- ▍Revenue ¥30.60B, +13,2% YoY
- ▍Operating income +71,1% YoY
- ▍Net income +62,1% YoY
- ▍Free cash flow +60,9% YoY
- ▍Net margin 4.7%
Revenue ¥27.03B, +1,0% YoY; Operating income +74,4% YoY.
- ▍Revenue ¥27.03B, +1,0% YoY
- ▍Operating income +74,4% YoY
- ▍Net income +64,9% YoY
- ▍Free cash flow +53,8% YoY
- ▍Net margin 3.3%
Revenue ¥26.76B, +30,1% YoY; Operating income +368,6% YoY.
- ▍Revenue ¥26.76B, +30,1% YoY
- ▍Operating income +368,6% YoY
- ▍Net income +301,7% YoY
- ▍Free cash flow +369,6% YoY
- ▍Net margin 2.0%
Revenue ¥20.58B; Operating income -¥203.1M.
- ▍Revenue ¥20.58B
- ▍Operating income -¥203.1M
- ▍Net margin -1.3%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 0,18 |
| Revenue | —no estimate | —no estimate | 39,2B CNY |
| Operating income | —no estimate | —no estimate | 2,6B CNY |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Alibaba Health Information Technology Ltd Market data — financials · 2026-05-26
- Alibaba Health Information Technology Ltd Market data — analyst estimates · 2026-05-26
- Alibaba Health Information Technology Ltd Market data — ESG · 2026-05-26